Calcimimetics: Physiology, results of preclinical and clinical studies, and perspectives;Calcimimétiques: Physiologie, résultats d'études cliniques et perspectives

Nephrologie et Therapeutique

Volumn 7, Issue 2, 2011, Pages 99-104

  Torres, Pablo Urena ^a,b  

^a Clinique du Landy   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Calcemia; Calcium receptor; Dialysis; Hyperparathyroidisme; Parathyroid hormone; Phosphatemia; Renal failure

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D DERIVATIVE;

ARTICLE; CALCIUM BLOOD LEVEL; DIALYSIS; FRACTURE; HUMAN; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; RISK; SECONDARY HYPERPARATHYROIDISM;

EID: 79953330516     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2010.12.010     Document Type: Short Survey

References (55)

1. P. Urena Parathyroid gland, calcium receptor and calcimimetics Nephrologie 23 2002 151 164 (Pubitemid 34685757)
2. E.M. Brown, G. Gamba, D. Riccardi, and M. Lombardi Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid Nature 366 1993 575 580 (Pubitemid 24035999)
3. X. Wang, W. Chen, N. Singh, and M. Promkan Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells Int J Oncol 36 2010 1573 1580
4. E.M. Brown Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int 14 Suppl. 3 2003 S25 S34
5. O. Ivanovski, I.G. Nikolov, N. Joki, and A. Caudrillier The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice Atherosclerosis 205 2009 55 62
6. S.H. Pearce, C. Williamson, O. Kifor, and M. Bai A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor N Engl J Med 335 1996 1115 1122 (Pubitemid 26330965)
7. M.R. Pollak, E.M. Brown, Y.H. Chou, and S.C. Hebert Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism Cell 75 1993 1297 1303
8. A.J. Brown, C.S. Ritter, J.L. Finch, and E.A. Slatopolsky Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate Kidney Int 55 1999 1284 1292 (Pubitemid 29157126)
9. O. Kifor, F.D. Moore Jr., P. Wang, and M. Goldstein Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism J Clin Endocrinol Metab 81 1996 1598 1606
10. N. Carrillo-Lopez, D. Alvarez-Hernandez, I. Gonzalez-Suarez, and P. Roman-Garcia Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol Nephrol Dial Transplant 23 2008 3479 3484
11. J. Silver, E. Moallem, R. Kilav, and A. Sela Regulation of the parathyroid hormone gene by calcium, phosphate and 1,25-dihydroxyvitamin D Nephrol Dial Transplant 13 1998 S40 S44
12. F.J. Mendoza, I. Lopez, R. Canalejo, and Y. Almaden Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats Am J Physiol Renal Physiol 296 2009 F605 F613
13. C. Valle, M. Rodriguez, R. Santamaria, and Y. Almaden Cinacalcet reduces the set point of the PTH-calcium curve J Am Soc Nephrol 19 2008 2430 2436
14. M. Denda, J. Finch, A.J. Brown, and Y. Nishii 1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats Kidney Int 50 1996 34 39 (Pubitemid 26323694)
15. M. Rodriguez, A.J. Felsenfeld, and F. Llach Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy Kidney Int 40 1991 1063 1068
16. E.F. Nemeth, M.E. Steffey, L.G. Hammerland, and B.C. Hung Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci U S A 95 1998 4040 4045 (Pubitemid 28173250)
17. J. Chin, S.C. Miller, M. Wada, and N. Nagano Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats J Am Soc Nephrol 11 2000 903 911 (Pubitemid 30241724)
18. J. Fox, S.H. Lowe, R.L. Conklin, and E.F. Nemeth The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism Endocrine 10 1999 97 103 (Pubitemid 29295782)
19. M. Nechama, I.Z. Ben-Dov, J. Silver, and T. Naveh-Many Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD Am J Physiol Renal Physiol 296 2009 F795 F800
20. M. Wada, Y. Furuya, J. Sakiyama, and N. Kobayashi The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor J Clin Invest 100 1997 2977 2983 (Pubitemid 28022834)
21. M. Wada, H. Ishii, Y. Furuya, and J. Fox NPS R-568 halts or reverses osteitis fibrosa in uremic rats Kidney Int 53 1998 448 453 (Pubitemid 28097862)
22. M. Wada, N. Nagano, Y. Furuya, and J. Chin Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism Kidney Int 57 2000 50 58 (Pubitemid 30227753)
23. E.F. Nemeth, W.H. Heaton, M. Miller, and J. Fox Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl J Pharmacol Exp Ther 308 2004 627 635 (Pubitemid 38134225)
24. R.Z. Harris, D. Padhi, T.C. Marbury, and R.J. Noveck Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily Am J Kidney Dis 44 2004 1070 1076 (Pubitemid 39556487)
25. W.G. Goodman, G.A. Hladik, S.A. Turner, and P.W. Blaisdell The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism J Am Soc Nephrol 13 2002 1017 1024 (Pubitemid 34274098)
26. L.D. Quarles, D.J. Sherrard, S. Adler, and S.J. Rosansky The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease J Am Soc Nephrol 14 2003 575 583 (Pubitemid 36246000)
27. P. Molina Vila, P. Sanchez Perez, E. Garrigos Almerich, and A. Peris Domingo Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in non hypercalcemic hemodialysis patients Hemodial Int 12 2008 73 79 (Pubitemid 351247381)
28. T.B. Drueke, and M. Touam Calcium balance in haemodialysis - do not lower the dialysate calcium concentration too much (con part) Nephrol Dial Transplant 24 2009 2990 2993
29. M. Touam, V. Menoyo, D. Attaf, and H.E. Thebaud High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism Kidney Int 67 2005 2065 [author reply 2065-6]
30. J. Cunningham Achieving therapeutic targets in the treatment of secondary hyperparathyroidism Nephrol Dial Transplant 19 Suppl. 5 2004 V9 V14
31. J.S. Lindberg, S.M. Moe, W.G. Goodman, and J.W. Coburn The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism Kidney Int 63 2003 248 254 (Pubitemid 35463928)
32. G.A. Block, K.J. Martin, A.L. de Francisco, and S.A. Turner Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 2004 1516 1525 (Pubitemid 38477776)
33. S.M. Sprague, P. Evenepoel, M.P. Curzi, and M.T. Gonzalez Simultaneous control of PTH and CaxP Is sustained over 3 years of treatment with cinacalcet HCl Clin J Am Soc Nephrol 4 2009 1465 1476
34. S.M. Moe, G.M. Chertow, J.W. Coburn, and L.D. Quarles Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl Kidney Int 67 2005 760 771 (Pubitemid 40139871)
35. W.L. St Peter, Q. Li, J. Liu, and M. Persky Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006 Clin J Am Soc Nephrol 4 2009 354 360
36. P. Urena, S.H. Jacobson, E. Zitt, and M. Vervloet Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study Nephrol Dial Transplant 24 2009 2852 2859
37. D.L. Regidor, C.P. Kovesdy, R. Mehrotra, and M. Rambod Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients J Am Soc Nephrol 19 2008 2193 2203
38. V. Belozeroff, W.G. Goodman, L. Ren, and K. Kalantar-Zadeh Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients Clin J Am Soc Nephrol 4 2009 673 679
39. H.H. Malluche, M.C. Monier-Faugere, G. Wang, and O.J. Fraza An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism Clin Nephrol 69 2008 269 278
40. J.B. Wetmore, S. Liu, R. Krebill, and R. Menard Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD Clin J Am Soc Nephrol 5 2009 110 116
41. P. Messa, L. Alberti, G. Como, and R. Cerutti Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients Nephrol Dial Transplant 22 2007 2724 2725 (Pubitemid 47365544)
42. G.F. Strippoli, S. Palmer, A. Tong, and G. Elder Meta-analysis of biochemical and patient-level effects of calcimimetic therapy Am J Kidney Dis 47 2006 715 726
43. A.L. de Francisco, M. Izquierdo, J. Cunningham, and C. Pinera Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet Nephrol Dial Transplant 23 2008 2895 2901
44. H. Komaba, S. Nakanishi, A. Fujimori, and M. Tanaka Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism Clin J Am Soc Nephrol 5 2010 2305 2314
45. M. Meola, I. Petrucci, and G. Barsotti Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism Nephrol Dial Transplant 24 2009 982 989
46. H. Terawaki, H. Nakano, F. Takeguchi, and T. Hasegawa Regression of parathyroid gland swelling by treatment with cinacalcet Nephrol Dial Transplant 24 2009 690 691 [author reply 691-2]
47. 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism Nucl Med Commun 30 2009 890 894
48. H. Komaba, J. Shin, and M. Fukagawa Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient Nephrol Dial Transplant 25 2010 638 641
49. L.D. Quarles, D. Spiegel, and M. Curzi The effects of 1-year treatment with the calcimimetic AMG-073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT) J Am Soc Nephrol 13 2002 572A
50. Y.H. Lien, A.L. Silva, and D. Whittman Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism Nephrol Dial Transplant 20 2005 1232 1237 (Pubitemid 40862116)
51. Raggi P, Chertow GM, Torres PU, Csiky B, et al. The Advance study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. First published online: December 8, 2010.
52. J. Cunningham, M. Danese, K. Olson, and P. Klassen Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 2005 1793 1800 (Pubitemid 43169924)
53. G.M. Chertow, L.B. Pupim, G.A. Block, and R. Correa-Rotter Evaluation of Cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview Clin J Am Soc Nephrol 2 2007 898 905
54. G.A. Block, D.M. Spiegel, J. Ehrlich, and R. Mehta Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis Kidney Int 68 2005 1815 1824 (Pubitemid 43169927)
55. W. Qunibi, and L.R. Muenz Progression of calcification in the calcium acetate renagel evaluation-2 (Care-2) Study Am J Kidney Dis 52 2008 1022 1023 [author reply 1023-4]